NASDAQ : MIRA
MIRA Pharmaceuticals, Inc. — Financial statements
Healthcare · Drug Manufacturers - General · United States
Last price 0.5716 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 24.02M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 7.26M | 8.77M | 4.71M | 6.95M | 4.70M | 1.47M |
| Research & Development | 2.14M | 1.72M | 3.31M | 1.57M | 2.35M | 684.45K |
| Operating Expenses | 9.40M | 10.49M | 8.02M | 8.53M | 7.05M | 2.15M |
| Operating Income | -9.40M | -10.49M | -8.02M | -8.53M | -7.05M | -2.15M |
| Interest Expense | -3.46M | -10.25K | -24.37K | |||
| Interest & Investment Income | 148.91K | 98.91K | 165.67K | |||
| Other Non Operating Income (Expenses) | -12.84K | -13.07K | ||||
| EBT Excluding Unusual Items | -9.44M | -10.41M | -7.85M | -11.98M | -7.06M | -2.18M |
| Gain (Loss) on Sale of Investments | -35.21K | -35.21K | ||||
| Pretax Income | -9.48M | -10.44M | -7.85M | -11.98M | -7.06M | -2.18M |
| Net Income | -9.48M | -10.44M | -7.85M | -11.98M | -7.06M | -2.18M |
| Preferred Dividends & Other Adjustments | 21.56M | 21.56M | ||||
| Net Income to Common | -31.04M | -32.00M | -7.85M | -11.98M | -7.06M | -2.18M |
| Shares Outstanding (Basic) | 36.01M | 23.69M | 15.44M | 13.92M | 17.57M | 12.67M |
| Shares Outstanding (Diluted) | 36.01M | 23.69M | 15.44M | 13.92M | 17.57M | 12.67M |
| EPS (Basic) | -0.86 | -1.35 | -0.51 | -0.86 | -0.40 | -0.17 |
| EPS (Diluted) | -0.86 | -1.35 | -0.51 | -0.86 | -0.40 | -0.17 |
| EBIT | -9.40M | -10.49M | -8.02M | -8.53M | -7.05M | -2.15M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.61M | 6.35M | 2.83M | 4.60M | 350.98K | 2.81M |
| Short-Term Investments | 4.50M | 4.68M | ||||
| Cash & Short-Term Investments | 8.11M | 11.03M | 2.83M | 4.60M | 350.98K | 2.81M |
| Other Receivables | 11.86K | |||||
| Receivables | 11.86K | |||||
| Prepaid Expenses | 54.29K | 28.15K | 54.73K | 243.80K | ||
| Other Current Assets | 143.43K | 100.00K | ||||
| Total Current Assets | 8.17M | 11.06M | 2.89M | 4.86M | 494.40K | 2.91M |
| Property, Plant & Equipment | 5.06K | 363.67K | ||||
| Long-Term Accounts Receivable | 69.15K | |||||
| Other Long-Term Assets | 35.44K | 35.44K | 35.44K | 445.61K | ||
| Total Assets | 8.20M | 11.09M | 2.92M | 4.93M | 858.07K | 3.36M |
| Accounts Payable | 40.82K | 129.20K | 723.35K | 538.56K | 905.55K | 776.01K |
| Accrued Expenses | 14.47K | 57.52K | 24.74K | |||
| Short-Term Debt | 572.87K | 133.06K | 293.06K | |||
| Current Portion of Leases | 5.06K | 273.90K | ||||
| Total Current Liabilities | 40.82K | 702.07K | 723.35K | 558.10K | 1.37M | 1.09M |
| Long-Term Leases | 84.27K | |||||
| Total Liabilities | 40.82K | 702.07K | 723.35K | 558.10K | 1.45M | 1.09M |
| Common Stock | 4.20K | 4.19K | 1.66K | 1.48K | 6.66K | 6.34K |
| Additional Paid-In Capital | 50.10M | 49.97M | 31.34M | 25.66M | 8.70M | 4.50M |
| Retained Earnings | -41.94M | -39.58M | -29.14M | -21.29M | -9.30M | -2.24M |
| Shareholders' Equity | 8.16M | 10.39M | 2.20M | 4.37M | -596.23K | 2.26M |
| Total Liabilities & Equity | 8.20M | 11.09M | 2.92M | 4.93M | 858.07K | 3.36M |
| Total Debt | 572.87K | 5.06K | 491.23K | 293.06K | ||
| Net Cash (Debt) | 8.11M | 10.46M | 2.83M | 4.60M | -140.25K | 2.52M |
| Net Cash Per Share | 0.23 | 0.44 | 0.18 | 0.33 | -0.01 | 0.20 |
| Filing Date Shares Outstanding | 42.02M | 42.02M | 16.81M | 14.78M | 13.31M | 12.67M |
| Total Common Shares Outstanding | 42.02M | 41.94M | 16.56M | 14.78M | 13.31M | 12.67M |
| Working Capital | 8.13M | 10.36M | 2.16M | 4.30M | -875.63K | 1.82M |
| Book Value Per Share | 0.19 | 0.25 | 0.13 | 0.30 | -0.04 | 0.18 |
| Tangible Book Value | 8.16M | 10.39M | 2.20M | 4.37M | -596.23K | 2.26M |
| Tangible Book Value Per Share | 0.19 | 0.25 | 0.13 | 0.30 | -0.04 | 0.18 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -9.48M | -10.44M | -7.85M | -11.98M | -7.06M | -2.18M |
| Loss (Gain) From Sale of Investments | 35.21K | 35.21K | ||||
| Stock-Based Compensation | 5.08M | 6.31M | 1.92M | 2.55M | 1.30M | |
| Other Operating Activities | 5.54M | 10.25K | 24.37K | |||
| Change in Accounts Payable | -257.63K | -594.15K | 184.78K | -389.52K | 152.08K | 776.01K |
| Change in Other Net Operating Assets | -194.14K | 26.58K | 186.46K | -250.16K | -5.50K | |
| Operating Cash Flow | -4.64M | -4.66M | -5.56M | -4.53M | -5.60M | -1.38M |
| Short-Term Debt Issued | 572.87K | 2.15M | 203.06K | |||
| Total Debt Issued | 224.16K | 572.87K | 2.15M | 203.06K | ||
| Short-Term Debt Repaid | -1.14M | -160.00K | ||||
| Total Debt Repaid | -330.61K | -1.14M | -160.00K | |||
| Net Debt Issued (Repaid) | -106.44K | 572.87K | 1.01M | -160.00K | 203.06K | |
| Issuance of Common Stock | 7.90M | 7.90M | 3.61M | 7.70M | 2.90M | 4.51M |
| Other Financing Activities | -270.99K | -292.47K | 182.42K | 74.28K | 402.19K | -526.73K |
| Financing Cash Flow | 7.52M | 8.18M | 3.79M | 8.78M | 3.15M | 4.18M |
| Net Cash Flow | 2.88M | 3.51M | -1.77M | 4.25M | -2.46M | 2.81M |
| Levered Free Cash Flow | -1.01M | -812.59K | -2.72M | -5.46M | -3.00M | -659.96K |
| Unlevered Free Cash Flow | -1.01M | -812.59K | -2.72M | -3.30M | -2.99M | -644.72K |
| Change in Working Capital | -451.78K | -567.56K | 371.25K | -639.69K | 146.58K | 776.01K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 23.74M | 63.23M | 18.88M | 15.52M | ||
| Enterprise Value | 15.63M | 55.70M | 14.73M | 9.76M | ||
| Last Close Price | 0.55 | 1.51 | 1.14 | 1.05 | ||
| PB Ratio | 2.82 | 6.08 | 8.58 | 3.55 | ||
| P/TBV Ratio | 2.82 | 6.08 | 8.58 | 3.55 | ||
| Debt / Equity Ratio | 0.06 | 0.00 | -0.82 | 0.13 | ||
| Net Debt / Equity Ratio | -0.99 | -1.01 | -1.29 | -1.05 | -0.23 | -1.11 |
| Quick Ratio | 198.75 | 15.71 | 3.92 | 8.27 | 0.26 | 2.57 |
| Current Ratio | 200.08 | 15.75 | 3.99 | 8.71 | 0.36 | 2.66 |
| Return on Equity (ROE) | -217.12% | -165.87% | -238.90% | -634.30% | -847.77% | -198.47% |
| Return on Assets (ROA) | -129.55% | -93.58% | -127.59% | -184.05% | -209.10% | -79.65% |
| Return on Capital Employed (ROCE) | -115.20% | -101.00% | -364.50% | -194.90% | 1,376.60% | -95.20% |
| Earnings Yield | -152.57% | -16.51% | -41.59% | -77.21% | ||
| Buyback Yield / Dilution | -115.16% | -53.42% | -10.91% | 20.73% | -38.60% |